Estimates of net prices and usage in the U.S. and other major markets
The report examines the actual cost of hepatitis C treatments across multiple countries, focusing on media reporting of net prices negotiated between manufacturers and intermediaries. It seeks to go beyond the typical examination of list prices that are often misleading. It also includes a country comparison of the infected population being treated for hepatitis C. The study was conducted independently by the IMS Institute with funding support from the Pharmaceutical Care Management Association (PCMA).
The report can be accessed here.